Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

The novel allosteric NEK7 inhibitor ofirnoflast (HT-6184) demonstrates robust and sustained hematologic response in subjects with IPSS-R very low, low or intermediate risk myelodysplastic syndrome (MDS) and symptomatic anemia

Varun Bafna, Sandip Shah, Arijit Nag, Prof. Uttam Kumar Nath, Chandran Nair, Ramesh Uppada, Devan Bursey, Andrea Groen, Victoria Allgood, Alan List, Stephen Anthony, David Bearss

Blood (2025) 146 (Supplement 1): 5622.

https://doi.org/10.1182/blood-2025-5622

Published: 2025

Journal Articles

Profiling drug sensitivity in CLL B cells after BTK inhibitor progression using a novel drug panel

Weiguo Han, Emmanuel Contreras Guzman, Aisharya Bhattacharya, Sutapa Sinha, Zhiquan Wang, Kari Rabe, Stephen Anthony, Nathanael Gray, Gerald Crabtree, Esteban Braggio, Saad Kenderian, Sameer Parikh, Neil Kay

Blood (2025) 146 (Supplement 1): 7407.

https://doi.org/10.1182/blood-2025-7407

Published: 2025

Journal Articles

Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib

Blood (2025) 146 (Supplement 1): 1532.

https://doi.org/10.1182/blood-2025-1532

Published: 2025

Journal Articles

Ofirnoflast, a novel inflammasome inhibitor, rewires transcriptional programs and shows clinical and preclinical efficacy in myeloid neoplasms

Blood (2025) 146 (Supplement 1): 323.

https://doi.org/10.1182/blood-2025-323

Published: 2025

Journal Articles

Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor

Jennifer Woyach, Danielle Brander, Boyu Hu, Kerry Rogers, Zulfa Omer, Emily Curran, Deborah Stephens, Andrea Sitlinger, Yi Chen, Stephen Anthony, Yu Chen, Kewei Shang, John Byrd

Blood (2025) 146 (Supplement 1): 87.

https://doi.org/10.1182/blood-2025-87

Published: 2025

Journal Articles

TP53 exon 7 (c.742C>T; p. Arg248Trp) vaf suppression by novel oral allosteric NEK7 inhibitor in a patient with low-risk myelodysplastic syndrome in A phase 2 clinical trial

Devan Bursey, Victoria Allgood, Andrea Groen, Jeremiah Bearss, Stephen Anthony, David Bearss

Blood (2025) 146 (Supplement 1): 7379.

https://doi.org/10.1182/blood-2025-7379

Published: 2025

Journal Articles

Targeting NLRP3 with ofirnoflast, alone or in combination with semaglutide, ameliorates inflammatory anemia associated with obesity-induced inflammation in rodent models

Benjamin Bearss, Jared Bearss, Chadwick Davis, Devan Bursey, William Burnett, Alexis Mollard, Jeremiah Bearss, Stephen Anthony, Margit Janat-Amsbury, David Bearss

Blood (2025) 146 (Supplement 1): 1127.

https://doi.org/10.1182/blood-2025-1127

Published: 2025

Journal Articles

Ofirnoflast suppresses heme-induced inflammation, representing a novel therapeutic strategy for hemolytic anemias

Benjamin Bearss, Jared Bearss, Devan Bursey, Alexis Mollard, Jeremiah Bearss, William Burnett, Chadwick Davis, Margit Janat-Amsbury, David Bearss, Stephen Anthony

Blood (2025) 146 (Supplement 1): 1151.

https://doi.org/10.1182/blood-2025-1151

Published: 2025

Journal Articles

The novel allosteric NEK7 inhibit ofirnoflast (HT-6184) reduces oxidized mitochondrial DNA in patients with low-risk myelodysplastic syndrome

Devan Bursey, Victoria Allgood, Andrea Groen, Jeremiah Bearss, Stephen Anthony, David Bearss

Blood (2025) 146 (Supplement 1): 2093.

https://doi.org/10.1182/blood-2025-2093

Published: 2025

Journal Articles

The novel allosteric NEK7 inhibitor ofirnoflast (HT-6184) suppresses IL-8 and other pro-inflammatory cytokines in patients with low-risk myelodysplastic syndrome and symptomatic anemia

Devan Bursey, Victoria Allgood, Andrea Groen, Jeremiah Bearss, Margit Janat-Amsbury, Stephen Anthony, David Bearss

Blood (2025) 146 (Supplement 1): 2092.

https://doi.org/10.1182/blood-2025-2092

Published: 2025

Journal Articles

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

Blood (2025) 146 (Supplement 1): 5136.

https://doi.org/10.1182/blood-2025-5136

Published: 2025

Journal Articles

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1- m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Blood (2024) 144 (Supplement 1): 214.

https://doi.org/10.1182/blood-2024-198218

Published: 2024

Journal Articles

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Blood (2024) 144 (Supplement 1): 213.

https://doi.org/10.1182/blood-2024-194827

Published: 2024

Journal Articles

A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Leukemic Activity of the Orally Available CDC-like Kinase Inhibitor, BH-30236, in Adults with R/R AML or HR-MDS

Eytan M. Stein, Leora Boussi, Alice Mims, Justin M. Watts, Gabriel N Mannis, Hongtao Liu, David Sallman, Farhad Ravandi, Gary J. Schiller, Eunice S. Wang, Brian J. Ball, J. Jean Cui, Jihao Zhou, Armin Graber, Zachary Zimmerman, Stephen Anthony Strickland

Blood (2024) 144 (Supplement 1): 5998.

https://doi.org/10.1182/blood-2024-204046

Published: 2024

Journal Articles

A First-in-Human, Phase 1, Dose Escalation Study of Sgr-2921 As Monotherapy in Subjects with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Courtney D. DiNardo, Stephen Anthony Strickland, Barry Skikne, Amer M. Zeidan, Elie Traer, Hetty E. Carraway, Stanley Frankel, Daniel E Weiss, Jacky H Wang, Steven Pirie-Shepherd, Joseph Piccotti, D. Hamish Wright, Karen Akinsanya

Blood (2023) 142 (Supplement 1): 1548.

https://doi.org/10.1182/blood-2023-186036

Published: 2023

Journal Articles

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)

Joshua F Zeidner, MD, Tara L Lin, MD, Carlos E Vigil, MD, Andrew Dalovisio, MD, Eunice S. Wang, MD, Moshe Yair Levy, MD, Mark G. Frattini, MD PhD, Daniel J. Lee, MD, Pau Montesinos, MD PhD, Juan Miguel Miguel Bergua Burgues, Jeffrey R. Schriber, MD, Stephen Anthony, DO, David J. Bearss, PhD, B. Douglas Smith, MD

Blood (2018) 132 (Supplement 1): 30.

https://doi.org/10.1182/blood-2018-99-115018

Published: 2018

Journal Articles

The CDK9 Inhibitor, Alvocidib, Potentiates the Non-Clinical Activity of Azacytidine or Decitabine in an MCL-1-Dependent Fashion, Supporting Clinical Exploration of a Decitabine and Alvocidib Combination

Wontak Kim, Clifford Whatcott, PhD, Adam Siddiqui-Jain, PhD, Stephen Anthony, DO, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2018) 132 (Supplement 1): 4355.

https://doi.org/10.1182/blood-2018-99-119793

Published: 2018

Journal Articles

A Phase 1 Study Evaluating Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Advanced Malignancies and Varying Degrees of Hepatic Impairment (HI)

Jennifer Brown, Ruth Plummer, Stephen Anthony, John Sarantopoulos, Filip De Vos, Mike White, Marco Schupp, Ying Ou, Ulka Vaishampayan

Blood (2016) 128 (22): 4496.

https://doi.org/10.1182/blood.V128.22.4496.4496

Published: 2016

Journal Articles

A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, In Older Patients with MDS Refractory to Hypomethylating Agents

Guillermo Garcia-Manero, MD, Selina Luger, MD, Parmeswaran Venugopal, MD, Lori Maness, MD, Meir Wetzler, MD, Jessica K Altman, MD, David F. Claxton, MD, Stephen Anthony Strickland, JR, MD, James M. Foran, MD, FRCPC, Stuart L Goldberg, MD, Judy Chiao, MD, Hagop M. Kantarjian, MD

Blood (2010) 116 (21): 1857.

https://doi.org/10.1182/blood.V116.21.1857.1857

Published: 2010

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

The novel allosteric NEK7 inhibitor ofirnoflast (HT-6184) demonstrates robust and sustained hematologic response in subjects with IPSS-R very low, low or intermediate risk myelodysplastic syndrome (MDS) and symptomatic anemia

Profiling drug sensitivity in CLL B cells after BTK inhibitor progression using a novel drug panel

Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib

Ofirnoflast, a novel inflammasome inhibitor, rewires transcriptional programs and shows clinical and preclinical efficacy in myeloid neoplasms

Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor

TP53 exon 7 (c.742C>T; p. Arg248Trp) vaf suppression by novel oral allosteric NEK7 inhibitor in a patient with low-risk myelodysplastic syndrome in A phase 2 clinical trial

Targeting NLRP3 with ofirnoflast, alone or in combination with semaglutide, ameliorates inflammatory anemia associated with obesity-induced inflammation in rodent models

Ofirnoflast suppresses heme-induced inflammation, representing a novel therapeutic strategy for hemolytic anemias

The novel allosteric NEK7 inhibit ofirnoflast (HT-6184) reduces oxidized mitochondrial DNA in patients with low-risk myelodysplastic syndrome

The novel allosteric NEK7 inhibitor ofirnoflast (HT-6184) suppresses IL-8 and other pro-inflammatory cytokines in patients with low-risk myelodysplastic syndrome and symptomatic anemia

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1- m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Leukemic Activity of the Orally Available CDC-like Kinase Inhibitor, BH-30236, in Adults with R/R AML or HR-MDS

A First-in-Human, Phase 1, Dose Escalation Study of Sgr-2921 As Monotherapy in Subjects with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)

The CDK9 Inhibitor, Alvocidib, Potentiates the Non-Clinical Activity of Azacytidine or Decitabine in an MCL-1-Dependent Fashion, Supporting Clinical Exploration of a Decitabine and Alvocidib Combination

A Phase 1 Study Evaluating Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Advanced Malignancies and Varying Degrees of Hepatic Impairment (HI)

A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, In Older Patients with MDS Refractory to Hypomethylating Agents

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only